RAPAMUNE*30CPR RIV 2MG ( DrugBank: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
67	Polycystic kidney disease	2

67. Polycystic kidney disease

Clinical trials : 216 / Drugs : 219 - (DrugBank : 50) / Drug target genes : 39 - Drug target pathways : 151

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-005047-21-IT (EUCTR)	24/12/2007	02/07/2008	Effects of Sirolimus on disease progression in patients with Autosomal Dominant Polycystic Kidney Di ...	Effects of Sirolimus on disease progression in patients with Autosomal Dominant Polycystic Kidney Di ...	Autosomal Dominant Polycystic Kidney Disease (ADPKD) MedDRA version: 9.1;Level: LLT;Classification c ...	Trade Name: RAPAMUNE100CPR RIV 1MG INN or Proposed INN: Sirolimus Trade Name: RAPAMUNE30CPR RIV 2MG I ...	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Italy
2	EUCTR2006-003427-37-IT (EUCTR)	05/02/2007	27/12/2006	Sirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and ...	Sirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and ...	Autosomal-Dominant Polycystic Kidney Disease ADPKD MedDRA version: 9.1;Level: LLT;Classification cod ...	Trade Name: RAPAMUNE30CPR RIV 1MG INN or Proposed INN: Sirolimus Trade Name: RAPAMUNE30CPR RIV 2MG IN ...	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes	16	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Italy

First Previous1Next Last